Home Mythic Therapeutics

Mythic Therapeutics

In operation
Series B
Antibody-Drug Conjugates (ADC) Developer
Basic
Enterprise Profile

Basic Information

Mythic Therapeutics has developed a series of antibody-drug conjugates (ADCs) designed to demonstrate unparalleled therapeutic index and efficacy. The company's FateControl technology specifically enhances ADC uptake in target tissues by manipulating the intracellular fate of ADCs, thereby expanding the range of diseases and patient profiles that can be treated with Mythic ADCs.
Mythic Therapeutics, Inc.
Massachusetts,United States of America
15~50 people
January 01, 2017
info@mythictx.com

Enterprise Profile

Industrial Sector
New Drug Development Biological Drug Production
Technology
Biotechnology
Concept
Therapeutic Products Department of Pharmacy
Application Scenarios
Innovative Drugs ADC (Antibody-Drug Conjugate)